These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 38183273)

  • 1. Evolocumab use in clinical practice in Switzerland: final data of the observational HEYMANS cohort study.
    Sudano I; Krähenbühl S; Mach F; Anstett A; Dhalwani N; Bridges I; Sibartie M; Ray KK
    Ther Adv Cardiovasc Dis; 2024; 18():17539447231213288. PubMed ID: 38183273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evolocumab is Initiated in Central and Eastern Europe at Much Higher LDL-C Levels Than Recommended in Guidelines: Results from the Observational HEYMANS Study.
    Blaha V; Margoczy R; Petrov I; Postadzhiyan A; Rašlová K; Rosolová H; Bridges I; Dhalwani NN; Zachlederova M; Ray KK
    J Cardiovasc Pharmacol Ther; 2023; 28():10742484231172847. PubMed ID: 37218974
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term treatment persistence and maintained reduction of LDL-cholesterol levels with evolocumab over 30 months: Results from the Spanish cohort of the European prospective HEYMANS study.
    Blanco Echevarría A; García Díaz JD; Caixas A; Plana Gil N; Rico Corral MÁ; Bridges I; Dhalwani N; Gatell Menchen S; Ray KK
    Clin Investig Arterioscler; 2023; 35(6):263-271. PubMed ID: 37236829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study.
    Ray KK; Dhalwani N; Sibartie M; Bridges I; Ebenbichler C; Perrone-Filardi P; Villa G; Vogt A; Bruckert E
    Eur Heart J Qual Care Clin Outcomes; 2022 Jun; 8(4):447-460. PubMed ID: 35175350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study.
    Lehrke M; Vogt A; Schettler V; Girndt M; Fraass U; Tabbert-Zitzler A; Bridges I; Dhalwani NN; Ray KK
    Adv Ther; 2024 Mar; 41(3):1184-1200. PubMed ID: 38286961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness, Adherence, and Safety of Evolocumab in a Swiss Multicenter Prospective Observational Study.
    Nanchen D; Carballo D; Bilz S; Rickli H; Koskinas KC; Mach F; Mueller C; Crljenica C; Rossi M; Reichert N; Sudano I
    Adv Ther; 2022 Jan; 39(1):504-517. PubMed ID: 34796465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolocumab effectiveness in the real-world setting: Austrian data from the pan-European observational HEYMANS study.
    Ebenbichler C; Drexel H; Hanusch U; Toplak H; Dhalwani NN; Bridges I; Hoelzl R; Hemetsberger M; Ray KK
    Wien Klin Wochenschr; 2024 Feb; 136(3-4):77-86. PubMed ID: 37525072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial.
    Nissen SE; Stroes E; Dent-Acosta RE; Rosenson RS; Lehman SJ; Sattar N; Preiss D; Bruckert E; Ceška R; Lepor N; Ballantyne CM; Gouni-Berthold I; Elliott M; Brennan DM; Wasserman SM; Somaratne R; Scott R; Stein EA;
    JAMA; 2016 Apr; 315(15):1580-90. PubMed ID: 27039291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
    Muccioli S; Giglio C; Annibali G; Cerutti E; Civera S; Casati R; Delnevo F; De Rosa C; Bongioanni S; Colopi M; Gandolfo N; Aranzulla T; Bianchi F; Blandino A; Borrione M; Grossi S; Luceri S; Mabritto B; Carceri C; Meliga E; Parrini I; Pizzuti A; Scrocca I; Sibona Masi A; Tomasello A; Gasco A; Musumeci G
    G Ital Cardiol (Rome); 2022 Jul; 23(7):553-561. PubMed ID: 35771021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study.
    Ray KK; Bruckert E; Peronne-Filardi P; Ebenbichler C; Vogt A; Bridges I; Sibartie M; Dhalwani N
    Atherosclerosis; 2023 Feb; 366():14-21. PubMed ID: 36696747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid profile of patients treated with evolocumab in Spanish hospital nephrology units (RETOSS NEFRO).
    Goicoechea M; Álvarez V; Segarra A; Polaina M; Martín-Reyes G; Robles NR; Escudero V; Orellana C; Bea Granell S; de Juan-Ribera J; Fernández Lucas M; Graña JM; Reque J; Sánchez Hernández R; Villamayor S; Górriz JL
    Nefrologia (Engl Ed); 2022; 42(3):301-310. PubMed ID: 36210619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
    Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
    Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study.
    Koren MJ; Sabatine MS; Giugliano RP; Langslet G; Wiviott SD; Kassahun H; Ruzza A; Ma Y; Somaratne R; Raal FJ
    JAMA Cardiol; 2017 Jun; 2(6):598-607. PubMed ID: 28291870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolocumab vs. Ezetimibe in Statin-Intolerant Hyperlipidemic Japanese Patients: Phase 3 GAUSS-4 Trial.
    Koba S; Inoue I; Cyrille M; Lu C; Inomata H; Shimauchi J; Kajinami K
    J Atheroscler Thromb; 2020 May; 27(5):471-484. PubMed ID: 31748467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical profile of patients treated with evolocumab in lipid/internal medicine units of Spain. Observational study (RETOSS-IMU).
    Masana L; López Miranda J; Civeira F; Reinares L; Guijarro C; Plana N; Cuenca R; Sánchez D; Hernández JL; Andrés R; Blanco A; Villamayor S
    Clin Investig Arterioscler; 2020; 32(5):183-192. PubMed ID: 32317124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy.
    Cho L; Rocco M; Colquhoun D; Sullivan D; Rosenson RS; Dent R; Xue A; Scott R; Wasserman SM; Stroes E
    Clin Cardiol; 2014 Mar; 37(3):131-9. PubMed ID: 24477778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multizonal observational study conducted by clinical practitioners on evolocumab use in subjects with hyperlipidemia in Saudi Arabia and Kuwait: Results from the ZERBINI study.
    Al Faraidy K; Akbar M; Shehri M; Aljarallah M; Abdin Hussein G; Dashti R; Al Qudaimi A; Al Nouri F; Awan Z; Essam A; Emara A
    PLoS One; 2023; 18(1):e0278821. PubMed ID: 36662739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.